SCHEMBL6207709

SCHEMBL6207709

CC(C)(C)C1CC(C(=O)O)(S(=O)(=O)c2cccs2)CCO1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
PKM P14618 1/20 0.36
POLB P06746 1/20 0.34
MMP1 P03956 1/20 0.34
MMP9 P14780 1/20 0.34
MMP13 P45452 1/20 0.34
ALDH1A1 P00352 5/20 0.33
APP P05067 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GCK P35557 2/20 0.32
HSD17B10 Q99714 1/20 0.32
HSD11B1 P28845 1/20 0.32
LMNA P02545 1/20 0.32
GCKR Q14397 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6227102 0.71 ALDH1A1 (0.36) RAB9AKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL6207707 0.71 CYP2C9 (0.43) RAB9AKMT2AMEN1PKMMMP1
SCHEMBL6272775 0.68
SCHEMBL6206625 0.66 RAB9A (0.46) RAB9AMMP1MMP9MMP13ALDH1A1
SCHEMBL6206253 0.57 MMP1 (0.46) PKMPOLBMMP1MMP9MMP13
SCHEMBL855231 0.57 L3MBTL1 (0.56) KMT2AMEN1PKMPOLBMMP1
Fluoride SCHEMBL27537666 0.56 F2 (0.52) KMT2AMEN1PKMPOLBALDH1A1
Benzene SCHEMBL11320361 0.56 F2 (0.52) KMT2AMEN1PKMPOLBALDH1A1
SCHEMBL5495317 0.56 ADAMTS5 (0.59) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
Ethane SCHEMBL27563851 0.55 F2 (0.50) PKMPOLBALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 RAB9A 3999/4885KMT2A 1113/4885MEN1 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.